Wide metabolite coverage LC-MS/MS assay for the diagnosis of inherited metabolic disorders in urine

The laboratory diagnosis of inherited metabolic disorders (IMD) has undergone significant development in recent decades, mainly due to the use of mass spectrometry, which allows rapid multicomponent analysis of a wide range of metabolites. Combined with advanced software tools, the diagnosis becomes...

Full description

Saved in:
Bibliographic Details
Published inTalanta (Oxford) Vol. 271; p. 125699
Main Authors Ivanovová, Eliška, Piskláková, Barbora, Dobešová, Dana, Janečková, Hana, Foltenová, Hana, Kvasnička, Aleš, Prídavok, Matúš, Bouchalová, Kateřina, de Sousa, Julie, Friedecký, David
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.05.2024
Subjects
Online AccessGet full text
ISSN0039-9140
1873-3573
1873-3573
DOI10.1016/j.talanta.2024.125699

Cover

More Information
Summary:The laboratory diagnosis of inherited metabolic disorders (IMD) has undergone significant development in recent decades, mainly due to the use of mass spectrometry, which allows rapid multicomponent analysis of a wide range of metabolites. Combined with advanced software tools, the diagnosis becomes more efficient as a benefit for both physicians and patients. A hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry assay for determination of urinary purines, pyrimidines, N-acylglycines, N-acetylated amino acids, sugars, sugar alcohols and other diagnostically important biomarkers was developed and validated. Evaluation of the results consisting of utilisation of robust scaling and advanced visualization tools is simple and even suitable for urgent requirements. The developed method, covering 65 biomarkers, provides a comprehensive diagnostic platform for 51 IMD. For most analytes, linearity with R2 > 0.99, intra and inter-day accuracy between 80 and 120 % and precision lower than 20 % were achieved. Diagnostic workflow was evaluated on 47 patients and External Quality Assurance samples involving a total of 24 different IMD. Over seven years, more than 2300 urine samples from patients suspected for IMD have been routinely analysed. This method offers the advantage of a broad coverage of intermediate metabolites of interest and therefore may be a potential alternative and simplification for clinical laboratories that use multiple methods for screening these markers. [Display omitted] •A sensitive and rapid LC-MS/MS method for the diagnosis of a wide range of inherited metabolic disorders.•Simultaneous determination of purines, pyrimidines, N-acylglycines, amino acids, sugars, sugar alcohols and other diagnostically relevant biomarkers in urine (together 65 biomarkers).•The analytical validation of the developed LC-MS/MS approach is extended by clinical validation on patient and external quality assurance samples.•The new approach using simple semi-automated sample evaluation is suitable for routine clinical laboratories dealing with urgent requirements.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0039-9140
1873-3573
1873-3573
DOI:10.1016/j.talanta.2024.125699